Mutual of America Capital Management LLC Cuts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mutual of America Capital Management LLC cut its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 178,688 shares of the biopharmaceutical company’s stock after selling 5,253 shares during the period. Mutual of America Capital Management LLC owned about 0.14% of Halozyme Therapeutics worth $10,228,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $33,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Halozyme Therapeutics in the second quarter worth approximately $49,000. Toth Financial Advisory Corp bought a new position in Halozyme Therapeutics during the third quarter valued at approximately $57,000. Finally, FSC Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter worth approximately $65,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $45.65 on Monday. The company has a market cap of $5.81 billion, a PE ratio of 15.12, a P/E/G ratio of 0.42 and a beta of 1.29. The business has a 50 day moving average of $56.04 and a 200 day moving average of $53.48. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 70,000 shares of company stock worth $4,042,500. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Benchmark reiterated a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. JMP Securities increased their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Piper Sandler lifted their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Finally, Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.